• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Vaccine . Insights Into the Protective Effects of Influenza Vaccination: More Hospitalizations but Lower Follow-Up Mortality During the 2014/15 Inf

tetano

Editor, Senior Moderator
Vaccine


. 2020 Jun 19;S0264-410X(20)30791-X.
doi: 10.1016/j.vaccine.2020.06.019. Online ahead of print.
Insights Into the Protective Effects of Influenza Vaccination: More Hospitalizations but Lower Follow-Up Mortality During the 2014/15 Influenza Season in a Swiss Cohort


Agne Ulyte[SUP] 1 [/SUP], Wenjia Wei[SUP] 2 [/SUP], Oliver Gruebner[SUP] 3 [/SUP], Caroline B?hler[SUP] 4 [/SUP], Beat Br?ngger[SUP] 4 [/SUP], Eva Blozik[SUP] 5 [/SUP], Holger Dressel[SUP] 6 [/SUP], Matthias Schwenkglenks[SUP] 2 [/SUP], Viktor von Wyl[SUP] 2 [/SUP]



Affiliations

Abstract

Background: Observational studies of influenza vaccination are criticized as flawed due to unmeasured confounding. The goal of this cohort study was to explore the value and role of secondary claims data to inform the effectiveness of influenza vaccination, while systematically trying to reduce potential bias.
Methods: We iteratively reviewed the components of the PICO approach to refine study design. We analyzed Swiss mandatory health insurance claims of adult patients with chronic diseases, for whom influenza vaccination was recommended in 2014. Analyzed outcomes were all-cause mortality, hospitalization with a respiratory infection or its potential complication, and all-cause mortality after such hospitalization, adjusting for clinical and health care use variables. Cox and multi-state models were applied for time-to-event analysis.
Results: Of 343,505 included persons, 22.4% were vaccinated. Vaccinated patients were on average older, had more morbidities, higher health care expenditures, and had been more frequently hospitalized. In non-adjusted models, vaccination was associated with increased risk of events. Adding covariates decreased the hazard ratio (HR) both for mortality and hospitalizations. In the full model, the HR [95% confidence interval] for mortality during season was 0.82 [0.77-0.88], and closer to null effect after season. In contrast, HR for hospitalizations was increased during season to 1.28 [1.15-1.42], with estimates closer to null effect after season. HR in multi-state models were similar to those in the single-outcome models, with HR of mortality after hospitalization negative both during and after season.
Conclusion: In patients with chronic diseases, influenza vaccination was associated with more frequent specific hospitalizations, but decreased risk of mortality overall and after such hospitalization. Our approach of iteratively considering PICO elements helped to consider various sources of bias in the study sequentially. The selection of appropriate, specific outcomes makes the link between intervention and outcome more plausible and can reduce the impact of confounding.

Keywords: Cohort study; Competing risks; Influenza vaccine; Switzerland; Vaccine effectiveness.
 
Back
Top Bottom